Published • loading... • Updated
Neuronetics Revenue Rises as Clinic Business Expands
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Neuronetics Revenue Rises as Clinic Business Expands
MALVERN, PA — Neuronetics (NASDAQ: STIM) reported higher first-quarter revenue driven by growth in its U.S. clinic operations following the Greenbrook acquisition, while the company narrowed losses and reduced cash used in operations. Revenue for the quarter ended March 31 increased 8% to $34.5 million from $32.0 million a year earlier. Net loss narrowed to $10.8 million, or $0.16 per share, from $12.7 million, or $0.21 per share, in the prior-y…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
